Citi Reiterates Neutral Rating on Arrowhead Pharma (ARWR)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/20/2026
Go back to Citi Reiterates Neutral Rating on Arrowhead Pharma (ARWR)
June 3, 2024 1:33 PM EDT
Leerink Partners analyst Mani Foroohar raised the price target on Arrowhead Pharma (NASDAQ: ARWR) to $29.00 (from $27.00) while maintaining a Market Perform rating.... More
June 3, 2024 7:32 AM EDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), a severe genetic disease with significant unmet need and no FDA approved therapies. PALISADE successfully met the primary endpoint of lowering triglycerides and met all key secondary endpoints,... More
May 30, 2024 6:13 AM EDT
RBC Capital analyst Luca Issi reiterated an Outperform rating and $50.00 price target on Arrowhead Pharma (NASDAQ: ARWR)
The analyst comments "We hosted CEO for Boston NDR and he came across as very confident on cardiometabolic (particularly on upcoming FCS data, differentiation to... More
